---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

Enamine

🌎 enamine.net

Enamine is a privately owned chemical company established in 1991, specializing in the synthesis of building blocks and small molecular weight compound libraries. The company supports pharmaceutical, biotech, and academic institutions with innovative chemistry solutions, offering services such as custom synthesis, compound library design, and lead optimization support. Enamine is recognized for having the world's largest reputable collection of chemical compounds tailored for the life sciences industry.

---

Enamine - Latest News and Updates

• Enamine researchers published a paper on the synthesis of enantioenriched chromanols and their spirocyclic analogs.
• Enamine has developed a product called Golden Fragments for crystallographic fragment screening.
• Enamine's latest research on 3,3-disubstituted oxetanes is a game-changer for drug discovery.
• Enamine's team conducted an extensive study on oxetanes, optimizing synthetic protocols for scaling up to 1 kg while maintaining ring stability, which aids drug development.
• Enamine co-authored a paper demonstrating that larger virtual libraries significantly improve hit rates and potency in drug discovery.

• Authors of a recent ChemRxiv publication on water-soluble bioisosteres of meta-benzenes are employees of Enamine.
• Enamine collaborated with the V. P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry to develop a synthesis of chiral sp³-enriched chromanols using kinetic enzymatic resolution.
• Enamine's HLL-460 Compound Library was used to screen and purchase compounds for PRMT5 inhibitor development, confirming their purity at over 95%.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.